PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsVenous thromboembolism
MeSH D054556 - venous thromboembolism
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D013923:Thromboembolism
55 Companies
15 Drugs
$
Success rate
D054556: 
Venous thromboembolism
8 Companies
5 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Accord HealthcareApixaban Apixaban Accord  2020-07-23   
Rivaroxaban Rivaroxaban Accord  2020-11-16   
Dabigatran etexilate Dabigatran Etexilate Accord  2023-05-26   
BayerRivaroxaban Xarelto  2008-09-30   
Berlin-ChemieEdoxaban Roteas  2017-04-19   
Boehringer IngelheimDabigatran etexilate Pradaxa  2008-03-17   
Bristol Myers SquibbApixaban Eliquis  2011-05-18 $13,442 M Q3/24-Q2/25 
Daiichi PharmaceuticalEdoxaban Lixiana  2015-06-19   
MylanRivaroxaban Rivaroxaban Viatris (previously Rivaroxaban Mylan)  2021-11-12   
Techdow Pharma NetherlandsEnoxaparin Inhixa  2016-09-15   
Clinical Trials
Historical Success Rate
Phase 1
75%
12/16
Phase 2
96%
22/23
Phase 3
60%
21/35
Approved: 6Overall Success rate: 43%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Bayer
Rivaroxaban,
Dabigatran,
Benzimidazole,
Aglatimagene besadenovec,
Menatetrenone,
Aspartame,
Nepidermin,
OSOCIMAB,
Troxerutin,
Retinol,
Histone-arginine methyltransferase carm1,
Surlorian
Boehringer Ingelheim
Dabigatran etexilate,
Benzocaine,
Dabigatran,
Benzimidazole,
Aspartame,
Nepidermin
Bristol Myers Squibb
Apixaban,
Bevifimod,
Contezolid,
Corticorelin,
Retinol,
Thromboprophylaxis
Daiichi Pharmaceutical
Edoxaban,
Benzocaine,
Dabigatran,
Benzimidazole,
Menatetrenone,
Retinol,
Thromboprophylaxis
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use